The acquisition, if completed, would dramatically transform Profusa's revenue profile, but the non-binding term sheet and required conditions create significant execution risk. Traders should watch for definitive agreement execution, due diligence updates, and shareholder vote timing.
Price Chart
Executive Summary
Profusa has signed a non-binding term sheet to acquire a privately held diagnostics company with estimated 2025 net revenues of $111 million, in a transformative deal that would create a public diagnostics company. The acquisition consideration includes 19.99% of Profusa's common stock and convertible preferred stock, along with a concurrent $7 million convertible note financing. Management changes accompany the announcement, with Jack Stover appointed CEO and Ben Hwang moving to President.
Key Facts
- Non-binding term sheet to acquire a commercial-stage diagnostics company (Dx Company) with estimated 2025 net revenues of approximately $111 million
- Profusa to issue 19.99% of its common stock plus non-voting convertible preferred stock as consideration
- Profusa's outstanding convertible notes and obligations to be exchanged for preferred stock
- Concurrent $7 million convertible note financing (12-month term, 9% OID, 7% interest, 18% default rate)
- Jack Stover appointed Executive Chairman and CEO; Ben Hwang becomes President; Liviu Goldenberg appointed independent director
- Transaction subject to due diligence, definitive agreements, regulatory approvals, and shareholder approval
Financial Impact
Target's estimated $111M revenue vs. Profusa's current $1M market cap; $7M convertible note financing adds debt
Risk Factors
- Transaction is non-binding and may not close; no definitive agreement yet
- Significant dilution to current shareholders via 19.99% common stock issuance and convertible preferred conversion
- $7 million convertible note with 9% OID and high default interest rate adds financial strain
- Requires regulatory and shareholder approvals, which may be uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-081560 |
| Document: ea029883201ex99-1.htm | 0001213900-26-081560 |
| Document: 0001213900-26-081560-index-headers.html | 0001213900-26-081560 |
| Document: 0001213900-26-081560-index.html | 0001213900-26-081560 |
| Document: 0001213900-26-081560.txt | 0001213900-26-081560 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $1.07 $1.02 | ▼ −4.67% | ▼ −3.66% | $0.7364 (−31.18%) |
Oct 15, 2026 12d ago | 8-K | $1.07 $1.02 | ▲ +4.67% | ▲ +3.66% | $0.7364 (+31.18%) |
Oct 9, 2026 17d ago | 8-K | $1.30 $0.9002 | ▲ +30.75% | ▲ +29.26% | $0.7364 (+43.35%) |
Oct 5, 2026 22d ago | 8-K | $1.75 $1.30 | ▼ −25.71% | ▼ −26.14% | $0.7364 (−57.92%) |
Sep 24, 2026 4w ago | Press Release | $3.03 $1.87 | ▼ −38.28% | ▼ −37.87% | $0.7364 (−75.70%) |
Sep 16, 2026 5w ago | 8-K | $1.78 $2.05 | ▼ −15.17% | ▼ −12.61% | $0.7364 (+58.63%) |
Sep 15, 2026 6w ago | 8-K | $1.83 $1.91 | ▲ +4.37% | ▲ +3.55% | $0.7364 (−59.76%) |
Sep 1, 2026 8w ago | 8-K | $2.88 $2.47 | ▲ +14.24% | ▲ +14.32% | $0.7364 (+74.43%) |
Aug 31, 2026 8w ago | 8-K | $3.00 $2.88 | ▼ −4.00% | ▼ −3.86% | $0.7364 (−75.45%) |
Aug 20, 2026 9w ago | 8-K | $7.57 $4.24 | ▲ +43.99% | ▲ +45.10% | $0.7364 (+90.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers